MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Becton Dickinson and Co

Open

SectorGezondheidszorg

202.97 -0.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

201.79

Max

204.89

Belangrijke statistieken

By Trading Economics

Inkomsten

-118M

303M

Verkoop

-272M

5.2B

K/W

Sectorgemiddelde

33.099

57.333

EPS

3.43

Dividendrendement

2

Winstmarge

5.863

Werknemers

70,000

EBITDA

-1.3B

453M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+31.64% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.00%

2.63%

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-15B

56B

Vorige openingsprijs

203.07

Vorige sluitingsprijs

202.97

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Becton Dickinson and Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2025, 22:09 UTC

Acquisities, Fusies, Overnames

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 nov 2024, 12:59 UTC

Winsten

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 nov 2024, 12:56 UTC

Winsten

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 aug 2024, 11:08 UTC

Winsten

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3 jun 2024, 11:18 UTC

Acquisities, Fusies, Overnames

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5 feb 2025, 21:56 UTC

Winsten

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 feb 2025, 21:54 UTC

Winsten

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 feb 2025, 21:54 UTC

Winsten

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 feb 2025, 21:53 UTC

Winsten

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 feb 2025, 21:30 UTC

Winsten

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 feb 2025, 21:30 UTC

Winsten

Becton Dickinson 1Q Rev $5.2B >BDX

5 feb 2025, 21:30 UTC

Winsten

Becton Dickinson 1Q Net $303M >BDX

5 feb 2025, 21:30 UTC

Winsten

Becton Dickinson 1Q EPS $1.04 >BDX

7 nov 2024, 11:36 UTC

Winsten

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 nov 2024, 11:35 UTC

Winsten

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 nov 2024, 11:30 UTC

Winsten

Becton Dickinson 4Q EPS $1.45 >BDX

7 nov 2024, 11:30 UTC

Winsten

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 nov 2024, 11:30 UTC

Winsten

Becton Dickinson 4Q Rev $5.4B >BDX

7 nov 2024, 11:30 UTC

Winsten

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1 aug 2024, 10:37 UTC

Winsten

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1 aug 2024, 10:35 UTC

Winsten

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1 aug 2024, 10:35 UTC

Winsten

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1 aug 2024, 10:30 UTC

Winsten

Becton Dickinson 3Q EPS $1.68 >BDX

1 aug 2024, 10:30 UTC

Winsten

Becton Dickinson 3Q Net $487M >BDX

1 aug 2024, 10:30 UTC

Winsten

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1 aug 2024, 10:30 UTC

Winsten

Becton Dickinson 3Q Rev $5B >BDX

4 jun 2024, 17:26 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 jun 2024, 15:30 UTC

Populaire aandelen

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3 jun 2024, 13:26 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 jun 2024, 12:25 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Peer Vergelijking

Prijswijziging

Becton Dickinson and Co Prognose

Koersdoel

By TipRanks

31.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 269.13 USD  31.64%

Hoogste 280 USD

Laagste 260 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Becton Dickinson and Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technische score

By Trading Central

199.12 / 207.26Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.